U.S., May 5 -- ClinicalTrials.gov registry received information related to the study (NCT07563738) titled 'A 2-part Phase 1/2 Open-label Trial on ODM-212' on April 08.
Brief Summary: An open-label, multi-site, multi-cohort phase 1/2 trial to be conducted in 2 parts (dose escalation and dose expansion/optimisation)
Study Start Date: March 27
Study Type: INTERVENTIONAL
Condition:
Mesothelioma
Pancreatic Cancer
NSCLC (Advanced Non-small Cell Lung Cancer)
Intervention:
DRUG: ODM-212
ODM-212 40mg tablet
DRUG: Ipilimumab and nivolumab
Ipilimumab: 1 mg/kg administered intravenously over 30 minutes every 6 weeks. Nivolumab: 360 mg administered intravenously over 30 minutes every 3 weeks.
DRUG: Gemcitabine and nab-paclitaxel
Nab-paclitax...